title: A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras.
abstract: The c-Met receptor tyrosine kinase has been implicated in cellular transformation induced by mutant Ras, a commonly activated proto-oncogene in non-small cell lung cancer (NSCLC). However, the role of c-Met has not been defined in K-ras-mutant NSCLC, a disease for which no effective targeted therapeutic options currently exist. To acquire a greater understanding of its role, we used genetic and pharmacologic approaches to inhibit c-Met in mice and cultured cells. In Kras(LA1) mice, which develop premalignant lung lesions that progress to multifocal lung adenocarcinomas owing to somatic mutations in K-ras, c-Met was expressed in multiple cell types within premalignant lung lesions, and high concentrations of HGF were detected in bronchoalveolar lavage samples. Short-term treatment with PHA-665752, a c-Met inhibitor, decreased the numbers of premalignant lung lesions and induced apoptosis in tumor cells and vascular endothelial cells within lesions. In cell culture, PHA-665752 induced apoptosis of a lung adenocarcinoma cell line derived from Kras(LA1) mice (LKR-13) and a murine lung endothelial cell line (MEC). c-Met depletion by siRNA transfection induced apoptosis of MECs but not LKR-13 cells. Collectively, these findings suggest that apoptosis was an on-target effect of PHA-665752 in MECs but not in LKR-13 cells. We conclude that PHA-665752 inhibited lung tumorigenesis in Kras(LA1) mice and may provide a novel therapeutic approach to the prevention of K-ras-mutant NSCLC.
authors.affiliation: Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: Yanan
authors.initials: Y
authors.lastname: Yang
authors.forename: Marie
authors.initials: M
authors.lastname: Wislez
authors.forename: Nobukazu
authors.initials: N
authors.lastname: Fujimoto
authors.forename: Ludmila
authors.initials: L
authors.lastname: Prudkin
authors.forename: Julie G
authors.initials: JG
authors.lastname: Izzo
authors.forename: Futoshi
authors.initials: F
authors.lastname: Uno
authors.forename: Lin
authors.initials: L
authors.lastname: Ji
authors.forename: Amy E
authors.initials: AE
authors.lastname: Hanna
authors.forename: Robert R
authors.initials: RR
authors.lastname: Langley
authors.forename: Diane
authors.initials: D
authors.lastname: Liu
authors.forename: Faye M
authors.initials: FM
authors.lastname: Johnson
authors.forename: Ignacio
authors.initials: I
authors.lastname: Wistuba
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Kurie
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects; D005455:Fluorescent Antibody Technique; D011905:Genes, ras / Q000502:physiology*; D007124:Immunoenzyme Techniques; D007211:Indoles / Q000627:therapeutic use*; D008168:Lung / Q000378:metabolism* / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D051379:Mice; D018345:Mice, Knockout; D010766:Phosphorylation / Q000187:drug effects; D011230:Precancerous Conditions / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects; D013450:Sulfones / Q000627:therapeutic use*; D046888:Tissue Array Analysis; D014407:Tumor Cells, Cultured
chemical_list: C480541:5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one; D007211:Indoles; D034741:RNA, Small Interfering; D013450:Sulfones; D019859:Proto-Oncogene Proteins c-met